20 articles
Scientists find phosphatidylcholine loss fragments mitochondrial networks with age — and supplementing it may help reverse the damage.
Scientists find declining phosphatidylcholine disrupts mitochondria with age — and replenishing it quickly restores youthful cell energy.
A new partnership brings standardized spermidine into US clinical settings, shifting longevity science from shelves to physician-guided care.
ProJenX completes enrollment for Prosetin's Phase 1b ALS trial, reporting strong safety data and target engagement at therapeutic doses.
Johns Hopkins researchers find that a protein producing 'rotten egg' gas in tiny amounts may protect memory and prevent brain damage.
Researchers identified polyunsaturated fatty acids that may help eliminate senescent cells linked to aging and disease.
A newly identified protein in yeast and humans helps degrade toxic alpha-synuclein, offering a fresh target for Parkinson's therapy.
Blocking the protein PTP1B boosted memory and cleared brain plaque in mice, with potential links to diabetes and obesity treatment.
Cognition Therapeutics patents a stable form of CT1812, advancing its Alzheimer's and dementia drug toward registrational trials.
Dasatinib and quercetin, a leading senolytic combo, unexpectedly reduced myelination in healthy mouse brains, mimicking multiple sclerosis damage.
Cognition Therapeutics gets FDA alignment on a registrational study for zervimesine, a promising oral drug for Lewy body dementia with psychosis.
An oral iron-targeting drug significantly slowed Multiple System Atrophy progression in a Phase 2 trial, with Phase 3 planning underway.
New mouse research finds the trendy D+Q senolytic combo severely damages myelin, raising red flags for longevity self-experimenters.
New research shows overexpressing somatostatin reduces brain inflammation and amyloid plaques while improving cognition in Alzheimer's mice.
Researchers identified the gene that transports queuosine, a micronutrient crucial for brain health and cancer defense, solving a decades-old mystery.
A GLP-1 receptor agonist targeting neuroinflammation is now in a 120-patient trial measuring brain volume preservation in progressive MS.
Rafael Holdings licenses MIT patent for cyclodextrin therapy targeting cholesterol transport failure in ApoE4-linked Alzheimer's disease.
Raising Sox9 levels in aging astrocytes reduced amyloid plaque buildup and protected memory in mouse models with existing Alzheimer's symptoms.
Cyclarity's UDP-003 passed its first human trial with zero serious side effects, successfully flushing toxic 7-ketocholesterol through urine.
New compounds targeting the cPLA2 enzyme may reduce Alzheimer's-linked brain inflammation, especially in high-risk APOE4 gene carriers.
